The abuse potential of α-piperidinopropiophenone (PIPP) and α-piperidinopentiothiophenone (PIVT), two new synthetic cathinones with piperidine ring substituent

Biomolecules and Therapeutics

Volumn 25, Issue 2, 2017, Pages 122-129

  Botanas, Chrislean Jun ^a   Yoon, Seong Shoon ^b   de la Peña, June Bryan ^a   dela Peña, Irene Joy ^a   Kim, Mikyung ^a   Woo, Taeseon ^a   Seo, Joung Wook ^b   Jang, Choon Gon ^c   Park, Kyung Tae ^d   Lee, Young Hun ^d   Lee, Yong Sup ^d   Kim, Hee Jin ^a   Cheong, Jae Hoon ^a  

^a Sahmyook University   (South Korea)

^b Korea Institute of Toxicology   (South Korea)

^c Sungkyunkwan University   (South Korea)

^d Kyung Hee University   (South Korea)

Author keywords

Abuse potential; Conditioned place preference; Locomotor sensitization; Self administration; Synthetic cathinones

Indexed keywords

ALPHA PIPERIDINOPENTIOTHIOPHENONE; ALPHA PIPERIDINOPROPIOPHENONE; CATHINONE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; PIPERIDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATOM; CONDITIONED PLACE PREFERENCE TEST; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RECEPTOR D1 GENE; DOPAMINE RECEPTOR D2 GENE; DOPAMINE TRANSPORTER GENE; DOPAMINERGIC ACTIVITY; DRUG ABUSE; GENE EXPRESSION REGULATION; LOCOMOTION; MALE; MOUSE; NONHUMAN; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; REINFORCEMENT; REWARD; SELF ADMINISTRATION TEST;

EID: 85015950726     PISSN: 19769148     EISSN: 20054483     Source Type: Journal    
DOI: 10.4062/biomolther.2016.241     Document Type: Article

References (31)

1. Adriani, W, and Laviola, G (2003). Elevated levels of impulsivity and reduced place conditioning with d-amphetamine: two behavioral features of adolescence in mice. Behav Neurosci. 117, 695-703.
2. Botanas, CJ, de la Peña, JB, Dela Pena, IJ, Tampus, R, Yoon, R, Kim, HJ, Lee, YS, Jang, CG, and Cheong, JH (2015). Methoxetamine, a ketamine derivative, produced conditioned place preference and was self-administered by rats: evidence of its abuse potential. Pharmacol Biochem Behav. 133, 31-36.
3. Botanas, CJ, Yoon, SS, de la Peña, JB, dela Peña, IJ, Kim, M, Woo, T, Seo, JW, Jang, CG, Park, KT, Lee, YH, Lee, YS, Kim, HJ, and Cheong, JH (2017). A novel synthetic cathinone, 2-(methylamino)-1-(naphthalen-2-yl) propan-1-one (BMAPN), produced rewarding effects and altered striatal dopamine-related gene expression in mice. Behav Brain Res. 317, 494-501.
4. Brandt, SD, Freeman, S, Sumnall, HR, Measham, F, and Cole, J (2011). Analysis of NRG ‘legal highs’ in the UK: identification and formation of novel cathinones. Drug Test Anal. 3, 569-575.
5. Carroll, F, Lewin, AH, Mascarella, SW, Seltzman, HH, and Reddy, PA (2012). Designer drugs: a medicinal chemistry perspective. Ann N Y Acad Sci. 1248, 18-38.
6. Coppola, M, and Mondola, R (2012). Synthetic cathinones: chemistry, pharmacology and toxicology of a new class of designer drugs of abuse marketed as “bath salts” or “plant food”. Toxicol Lett. 211, 144-149.
7. de la Peña, JB, Lee, HC, Ike, C, Woo, TS, Yoon, SY, Lee, HL, Han, JS, Lee, JI, Cho, YJ, Shin, CY, and Cheong, JH (2012). Rewarding and reinforcing effects of the NMDA receptor antagonist-benzodiazepine combination, zoletil®: Difference between acute and repeated exposure. Behav Brain Res. 233, 434-442.
8. European Monitoring Centre for Drugs and Drug Addiction (2015). Injection of synthetic cathinones [cited 2016 Sep 25].Available from: http://www.emcdda.europa.eu/topics/pods/synthetic-cathinonesinjection/.
9. Everitt, BJ, and Robbins, TW (2013). From the ventral to the dorsal striatum: devolving views of their roles in drug addiction. Neurosci Biobehav Rev. 37, 1946-1954.
10. Gao, F, Wang, Y, Shi, D, Zhang, J, Wang, M, Jing, X, Humphry-Baker, R, Wang, P, Zakeeruddin, SM, and Grätzel, M (2008). Enhance the optical absorptivity of nanocrystalline TiO2 film with high molar extinction coefficient ruthenium sensitizers for high performance dye-sensitized solar cells. J Am Chem Soc. 130, 10720-10728.
11. Gatch, MB, Taylor, CM, and Forster, MJ (2013). Locomotor stimulant and discriminative stimulus effects of ‘bath salt’ cathinones. Behav Pharmacol. 24, 437-447.
12. German, CL, Fleckenstein, AE, and Hanson, GR (2014). Bath salts and synthetic cathinones: an emerging designer drug phenomenon. Life Sci. 97, 2-8.
13. Goldstein, RZ, and Volkow, ND (2002). Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am. J. Psychiatry. 159, 1642-1652.
14. Hwang, JY, Kim, JS, Oh, JH, Hong, SI, Ma, SX, Jung, YH, Ko, YH, Lee, SY, Kim, HC, and Jang, CG (2015). The new stimulant designer compound pentedrone exhibits rewarding properties and affects dopaminergic activity. Addict Biol.
15. Karila, L, Megarbane, B, Cottencin, O, and Lejoyeux, M (2015). Synthetic cathinones: a new public health problem. Curr Neuropharmacol. 13, 12-20.
16. Karlsson, L, Andersson, M, Kronstrand, R, and Kugelberg, FC (2014). Mephedrone, methylone and 3, 4-methylenedioxypyrovalerone (MDPV) induce conditioned place preference in mice. Basic Clin Pharmacol Toxicol. 115, 411-416.
17. Koob, GF, and Le Moal, M (2002). Neurobiology of drug addiction. Stages and pathways of drug involvement: examining the gateway hypothesis. New York: Cambridge University Press, pp. 337-361
18. Lagoja, IM, Pannecouque, C, Van Aerschot, A, Witvrouw, M, Debyser, Z, Balzarini, J, Herdewijn, P, and De Clercq, E (2003). Naminoimidazole derivatives inhibiting retroviral replication via a yet unidentified mode of action. J Med Chem. 46, 1546-1553.
19. Lisek, R, Xu, W, Yuvasheva, E, Chiu, YT, Reitz, AB, Liu-Chen, LY, and Rawls, SM (2012). Mephedrone (‘bath salt’) elicits conditioned place preference and dopamine-sensitive motor activation. Drug Alcohol Depend. 126, 257-262.
20. Meltzer, PC, Butler, D, Deschamps, JR, and Madras, BK (2006). 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 49, 1420-1432.
21. Metzger, RR, Haughey, HM, Wilkins, DG, Gibb, JW, Hanson, GR, and Fleckenstein, AE (2000). Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia. J Pharmacol Exp Ther. 295, 1077-1085.
22. Paillet-Loilier, M, Cesbron, A, Le Boisselier, R, Bourgine, J, and Debruyne, D (2014). Emerging drugs of abuse: current perspectives on substituted cathinones. Subst Abuse Rehabil. 5, 37-52.
23. Prosser, JM, and Nelson, LS (2012). The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol. 8, 33-42.
24. Prus, AJ, James, JR, and Rosecrans, JA (2009). Conditioned place preference. In Methods of Behavior Analysis in Neuroscience. 2, 59-76.
25. Rodriguez-Alarcón, G, Canales, J, and Salvador, A (2007). Rewarding effects of 3, 4-methylenedioxymethamphetamine (“Ecstasy”) in dominant and subordinate OF-1 mice in the place preference conditioning paradigm. Prog. Neuropsychopharmacol. Biol. Psychiatry. 31, 191-199.
26. Tampus, R, Yoon, SS, de la Pena, JB, Botanas, CJ, Kim, HJ, Seo, JW, Jeong, EJ, Jang, CG, and Cheong, JH (2015). Assessment of the abuse liability of synthetic cannabinoid agonists JWH-030, JWH-175, and JWH-176. Biomol. Ther. (Seoul). 23, 590-596.
27. VanGuilder, HD, Vrana, KE, and Freeman, WM (2008). Twenty-five years of quantitative PCR for gene expression analysis. Biotechniques. 44, 619-626.
28. Watterson, LR, and Olive, MF (Array). Synthetic cathinones and their rewarding and reinforcing effects in rodents. Adv. Neurosci. (Hindawi), 209875.
29. Xu, P, Qiu, Y, Zhang, Y, Bai, Y, Xu, P, Liu, Y, Kim, JH, and Shen, HW (2016). The Effects of 4-Methylethcathinone on Conditioned Place Preference, Locomotor Sensitization, and Anxiety-Like Behavior: A Comparison with Methamphetamine. Int J Neuropsychopharmacol. 19, pyv120.
30. Zakharova, E, Leoni, G, Kichko, I, and Izenwasser, S (2009). Differential effects of methamphetamine and cocaine on conditioned place preference and locomotor activity in adult and adolescent male rats. Behav Brain Res. 198, 45-50.
31. Zhu, J, and Reith, M (2008). Role of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse. CNS Neurol. Disord. Drug Targets. 7, 393-409.